Does Rallies show live market data for INTS?

Rallies combines live market context with ticker research for INTS, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

INTS (Intensity Therapeutics, Inc. Common stock) Stock Analysis

Intensity Therapeutics, Inc. Common stock (INTS) is a publicly traded Healthcare sector company. As of May 21, 2026, INTS trades at $4.58 with a market cap of $12.38M and a P/E ratio of -0.54. INTS moved +0.87% today. Year to date, INTS is -53.23%; over the trailing twelve months it is -55.35%. Its 52-week range spans $4.50 to $100.00. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces INTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest INTS stock research?

Intensity Therapeutics, Inc. Common stock (INTS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. INTS moved +0.87% today. Analyst consensus is buy.

INTS Key Metrics

Key financial metrics for INTS
Metric	Value
Price	$4.58
Market Cap	$12.38M
P/E Ratio	-0.54
EPS	$-8.56
Dividend Yield	0.00%
52-Week High	$100.00
52-Week Low	$4.50
Volume	25.07K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-11.61M
Gross Margin	0.00%

Latest INTS News

Intensity Therapeutics Wins 2026 Cancer Treatment Technology Innovator Award — May 14, 2026
Intensity Therapeutics Reports Q1 Net Loss $2.4M, 71.4% pCR in TNBC Study — May 7, 2026
Intensity Therapeutics Earns Platinum Pinnacle Award for INT230-6 Intratumoral Platform — Apr 15, 2026
Intensity Raises $20M, Extends Runway to Q2 2027; 71% pCR in TNBC — Mar 27, 2026
Intensity Therapeutics Secures US Patent No. 12,496,345, Expands IP to 41 Countries — Mar 24, 2026

INTS Analyst Consensus

2 analysts cover INTS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about INTS

What can I research for INTS on Rallies?: Intensity Therapeutics, Inc. Common stock (INTS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. INTS moved +0.87% today. Analyst consensus is buy.
Does Rallies show live market data for INTS?: Rallies combines live market context with ticker research for INTS, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.